Rubicon Genomics, Inc. is a leader in development and application of effective methods to analyze human DNA for genome-wide genotyping and haplotyping. The company is developing its proprietary OmniPlex technology as an integrated platform for archiving, amplifying and analyzing patient DNA for drug target discovery, pharmacogenomics and diagnostics. Single-site, multiple-site or whole genome amplification can be done using small samples of DNA that have been archived as OmniPlex DNA. Rubicon technology will make genome-wide SNP scoring faster, more accurate, more robust and less expensive. Rubicon will partner with pharmaceutical and diagnostic companies, as well as the makers of instruments and reagents to bring OmniPlex technology to the widest market - increasing the pipeline of more effective and safer drugs and ushering in the practice of gene-based medicine.